This paper aimed to review the clinical data on dapagliflozin (Forxiga®) treatment in the light of the recent DECLARE-TIMI 58 trial results. This study involving Type 2 diabetic patients, either with or without prior macroangiopathy, has demonstrated cardiovascular benefits in terms of the primary efficacy outcome, namely a composite of cardiovascular death and hospitalization for heart failure. Moreover, the study has revealed a lower risk for renal disease progression.
Key Words
Dapagliflozin, DECLARE-TIMI 58, primary and secondary cardiovascular prevention, cardiovascular events, heart failure, nephropathy